# Clinical Trials Data EGFR - Document 108

# Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT00899405

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Histologically or cytologically confirmed lung cancer\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* May have received prior EGFR inhibitors",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with lung cancer",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Potentially yes. The criteria state "histologically or cytologically confirmed lung cancer" and allows for prior EGFR inhibitor treatment. The presence of an EGFR mutation itself is not an exclusion criterion. In fact, patients with EGFR mutations are commonly treated with EGFR inhibitors, suggesting this trial might be \*targeting\* such patients. However, it's crucial to note that \*\*more information is needed\*\*. "Not specified" under patient characteristics is a red flag. There could be other inclusion/exclusion criteria related to EGFR mutation type, disease stage, performance status, etc., that are not listed here.  
  
\*\*Therefore, a patient with an EGFR mutation \*might\* be eligible, but it's essential to consult the full clinical trial protocol to be certain.\*\*